Ovation will produce the active ingredient in Oncaspar.
Ovation Pharmaceuticals will supply the active ingredient used in the production of Enzon Pharmaceuticals’ acute lymphoblastic leukemia (ALL) treatment. Oncaspar is a form of L-asparaginase enhanced with Enzon’s PEGylation technology.
The deal was signed after the expiration of a previous agreement between the two companies on December 31, 2006. Ovation has thus agreed to supply a sufficient quantity of L-asparaginase material through 2009. In addition, Enzon will make an upfront payment for a nonexclusive license to the cell line owned by Ovation from which the L-asparaginase material is currently sourced.
Enzon expects to transfer manufacturing and technology involving the cell line to its own supplier by December 31, 2009 to ensure long-term availability of the L-asparaginase material.